SRSF2 and myelodysplastic syndrome: The overall survival (OS) of MDS patients with SRSF2 mutation (median 10 months, 95% confidence interval 7.8–12.1 months) was shorter than those without mutation (median 23 months, 95% confidence interval 17.1–28.9 months) (P = 0.069, Fig. 5A).